| abstract |
The present invention provides an antibody conjugate with binding specificity for CD74, wherein according to the Kabat, Chothia or EU numbering scheme, the antibody is selected from the group consisting of HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC-S190, HC- Unnatural amino acids are included at positions of the group consisting of K222, HC-R19, HC-Y52 or HC-S70, and compositions comprising the antibody conjugates, including pharmaceutical compositions, and methods for preparing the conjugates , and methods of treatment using the conjugates and compositions. |